Loading
Ear and Head Tumors · Journal article
The Laryngoscope · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective administrative database study describes contemporary surgical and adjuvant treatment patterns for 811 patients with surgically treated temporal bone carcinoma from 2015 to 2024. Postoperative radiation therapy was the most common adjuvant treatment (23.1%), and its receipt was associated with more extensive surgical procedures (parotidectomy, neck dissection, or both), likely reflecting greater disease burden. The study characterizes epidemiology and treatment trends but does not measure clinical outcomes or comparative effectiveness.
Retrospective cohort study (administrative database analysis). Patients with surgically treated temporal bone malignancies identified from administrative database; mean age 70.9 years, 82.1% male, 89.5% non-Hispanic, 89.3% White; 40.3% South, 29.0% Midwest, 74.1% metropolitan residence.. Intervention: Surgically treated temporal bone carcinoma (external auditory canal excision, temporal bone resection, mastoidectomy); parotidectomy and/or neck dissection; postoperative radiation therapy (in 23.1%).. n = 811. United States (Cosmos database; state distribution reported: South, Midwest, others).
811 patients analyzed; mean age 70.9 years, 82.1% male, 89.5% non-Hispanic, 89.3% White Squamous cell carcinoma was the most common histological subtype at 63.4% Postoperative radiation therapy utilized in 23.1% of patients; immunotherapy and chemotherapy alone rarely used
No patient outcomes reported (survival, recurrence, disease-free interval, toxicity); univariable analysis without adjustment for confounders or disease severity metrics.
This study documents that postoperative radiation is the dominant adjuvant treatment for surgically resected temporal bone cancer, used in about 1 in 4 patients, and is significantly more common after extensive surgery suggesting treatment allocation reflects perceived disease extent. Clinicians should recognize these patterns as descriptive of current practice rather than as evidence of optimal outcomes; no survival, recurrence, or quality-of-life data are provided to guide treatment decisions.
Retrospective observational analysis of treatment patterns in a rare disease using administrative data; describes current practice and associations but lacks comparative effectiveness evidence or hard clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This study documents that postoperative radiation is the dominant adjuvant treatment for surgically resected temporal bone cancer, used in about 1 in 4 patients, and is significantly more common after extensive surgery suggesting treatment allocation reflects perceived disease extent. Clinicians should recognize these patterns as descriptive of current practice rather than as evidence of optimal outcomes; no survival, recurrence, or quality-of-life data are provided to guide treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
OBJECTIVES: To characterize the sociodemographic features of patients with temporal bone carcinoma and evaluate current treatment patterns. METHODS: This study analyzed data from the Cosmos database (2015-2024) to identify patients with surgically treated temporal bone malignancies using ICD-10 codes (C44.21, C44.22, and C44.29) and CPT codes for external auditory canal excision, temporal bone resection (69535), and mastoidectomy procedures. Demographic, clinical, and treatment variables, including parotidectomy, neck dissection, and perioperative therapy, were extracted. Univariable analyses were performed to assess factors associated with receipt of postoperative radiation therapy. RESULTS: A total of 811 patients were included. The mean age was 70.9 years, and 666 patients (82.1%) were male, non-Hispanic (726, 89.5%), and White (724, 89.3%). Squamous cell carcinoma was the most common histological subtype (63.4%). Patients most commonly resided in the South (327, 40.3%) and Midwest (235, 29.0%), with 74.1% residing in metropolitan areas. Socioeconomic status and social vulnerability index distributions were relatively even. Overall, 56.4% of patients underwent parotidectomy, neck dissection, or both. Postoperative radiation therapy was the most frequently utilized adjuvant treatment (23.1%), while immunotherapy and chemotherapy alone were rarely used. On univariable analysis, parotidectomy (OR = 1.73, 95% CI: 1.02-2.89), neck dissection (OR = 3.29, 95% CI: 1.78-5.99), and combined procedures (OR = 3.13, 95% CI: 2.13-4.65) were associated with higher odds of receiving postoperative radiation. CONCLUSION: Temporal bone carcinoma primarily affects older, White male patients. Postoperative radiation therapy is the most frequently utilized adjuvant treatment and is associated with more extensive surgical management, likely reflecting greater disease extent.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.